Companies: 10,795·Total market cap: $144.5T
Kaleido Biosciences, Inc.

Kaleido Biosciences, Inc.

KLDOOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$4262
P/E Ratio
52W High$0.19
52W Low$0.00001
SEC Filings

Kaleido Biosciences, Inc. (KLDO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001751299 · KLDO · OTC · as of Jun 8, 2026

Filing snapshot

203
Total Filings
SC 13G/A
Latest Form
2022-05-10
Most Recent
2019
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001751299 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2022-04-01
Fiscal Year End
Apr 1, 2022
Accession No.
0000950170-22-005256
Primary Document
kldo-20211231.htm
Source: data.sec.gov · CIK 0001751299 · Accession 0000950170-22-005256

Latest Key Filings

10-QQuarterly Report
10-Q
2021-11-01
8-KCurrent Report
8-K
2022-04-08Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2022-05-10
View
15-12B15-12B
15-12B
2022-05-06
View
EFFECTEFFECT
EFFECT
2022-04-29
View
S-8 POSS-8 POS
S-8 POS
2022-04-25
View
S-8 POSS-8 POS
S-8 POS
2022-04-25
View
S-8 POSS-8 POS
S-8 POS
2022-04-25
View
POS AMPOS AM
POS AM
2022-04-25
View
2525
25
2022-04-18
View
8-KCurrent Report
8-K
2022-04-08
View
NT 10-KNT 10-K
NT 10-K
2022-04-01
View
10-KAnnual Report
10-K
2022-04-01
View
8-KCurrent Report
8-K
2022-03-17
View
8-KCurrent Report
8-K
2022-03-09
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2022-02-09
View
8-KCurrent Report
8-K
2022-01-28
View
Showing 1–15 of 142 filingsForm 4 / 144 hidden· 203 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001751299  |  Exchange: OTC · Healthcare

Kaleido Biosciences, Inc. (OTC: KLDO) has submitted 203 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2019. As a Healthcare sector company with CIK 0001751299, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Kaleido Biosciences, Inc.'s most comprehensive regulatory disclosure. The most recent Kaleido Biosciences, Inc. 10-K was filed on 2022-04-01 for fiscal year ending 2022. Historical KLDO 10-K annual reports are available from 2018 through 2022.

Investors researching Kaleido Biosciences, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

KLDO SEC Filings · 8 questions

Kaleido Biosciences, Inc. (KLDO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 203 filings and access original documents at no cost. Kaleido Biosciences, Inc.'s CIK is 0001751299.

KLDO SEC filingsKaleido Biosciences, Inc. SEC documentsfind KLDO 10-K